SANA

SEC source: 0001562180-23-005027 · primarydocument.xml · derivative · entry 1

Cole Douglas G. · CIK 0001486373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005025 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005026 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005031 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005029 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005089 · primarydocument.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0000899243-23-014953 · doc4.xml · nonDerivative · entry 4

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,380,277

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-014953 · doc4.xml · nonDerivative · entry 3

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 10,743,293

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-014953 · doc4.xml · nonDerivative · entry 2

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,403,037

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.415, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-014953 · doc4.xml · nonDerivative · entry 1

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 10,920,533

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.415, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 6

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,425,334

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 5

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 11,101,994

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 4

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,434,664

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 3

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 11,174,664

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 2

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,447,791

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-013992 · doc4.xml · nonDerivative · entry 1

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 11,276,909

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001562180-23-003514 · primarydocument.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · EVP & President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,100,000

Underlying: Common Stock · 1,100,000 shares

Expires 2033-04-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on April 10, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-003475 · primarydocument.xml · nonDerivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,314

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-23-003474 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,760,888

F1 · shares: Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program.

SEC source: 0001562180-23-002394 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director · Head of SanaX

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-002396 · primarydocument.xml · derivative · entry 1

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-002397 · primarydocument.xml · derivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-002398 · primarydocument.xml · derivative · entry 1

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-002395 · primarydocument.xml · derivative · entry 1

Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-23-000267 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,753,172

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-23-000268 · primarydocument.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,353

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-007109 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,746,470

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-007110 · primarydocument.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-006711 · primarydocument.xml · derivative · entry 1

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2032-09-14

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on September 15, 2023 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-22-005623 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,742,458

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-005622 · primarydocument.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 496

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-005121 · primarydocument.xml · derivative · entry 6

MacDonald James J. · CIK 0001830054 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,954

Underlying: Common Stock · 66,796 shares

Expires 2030-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying the option vested and became exercisable on February 14, 2021, and the remainder of the shares underlying the option vest at a rate of 1/36th per month thereafter.

SEC source: 0001562180-22-005121 · primarydocument.xml · nonDerivative · entry 2

MacDonald James J. · CIK 0001830054 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,396

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-004943 · primarydocument.xml · derivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004945 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004942 · primarydocument.xml · derivative · entry 1

Cole Douglas G. · CIK 0001486373 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004940 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004939 · primarydocument.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004941 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004946 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-004944 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2032-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022.

SEC source: 0001562180-22-005121 · primarydocument.xml · nonDerivative · entry 1

MacDonald James J. · CIK 0001830054 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,600

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock of Sana Biotechnology, Inc. (the "Issuer") pursuant to the Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of November 17, 2021 through May 13, 2022. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 13, 2022.

SEC source: 0001562180-22-003313 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,739,130

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-003312 · primarydocument.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-22-002871 · primarydocument.xml · nonDerivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,250

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.14 to $7.40, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001562180-22-002428 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director · Head of SanaX

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-22-002429 · primarydocument.xml · derivative · entry 1

AGARWAL SUNIL · CIK 0001616640 · EVP, Head of Development & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-22-002430 · primarydocument.xml · derivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 760,000

Underlying: Common Stock · 760,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-22-002427 · primarydocument.xml · derivative · entry 1

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.

SEC source: 0001562180-22-002426 · primarydocument.xml · derivative · entry 1

MacDonald James J. · CIK 0001830054 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.